title: Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study.
abstract: OBJECTIVE
  To compare the effect of orbital floor (OFTA) or intravitreal (IVTA) administration of triamcinolone acetonide on visual acuity and chronic cystoid macular edema (CME) in patients with uveitis.
  
  
  METHODS
  Retrospective study of patients suffering from chronic noninfectious uveitis in whom CME (n = 97) did not respond to systemic corticosteroids and/or immunosuppression combined with acetazolamide. Patients received a single injection of either IVTA (n = 48, group 1) or OFTA (n = 49, group 2). Best-corrected visual acuity, macular edema (fluorescein angiography), uveitis activity, ocular hypertension, and cataract formation were analyzed over the course of 1 year.
  
  
  RESULTS
  Improvement in visual acuity (> or = 2 lines, LogMAR) was noted in 50% (IVTA) and 34% (OFTA) after 3 months (p = 0.23), and in 18% (IVTA) and 20% (OFTA) after 12 months. CME improved in 100% (IVTA) and 76% (OFTA) of the eyes within the first month postoperatively (p = 0.36). Macular edema was reduced in 100% (group 1) and 20% (group 2) after 3 months (p < 0.01). At 1 year, cataract progression was noted in 68% (IVTA) and 27% (OFTA) (p < 0.01). Increased intraocular pressure (>21 mm Hg) was detected in 21% (IVTA) and 0% (OFTA) at 4 weeks (p < 0.01) after injection.
  
  
  CONCLUSIONS
  Uveitic CME and visual acuity not responding to systemic immunosuppression and acetazolamide may improve after an IVTA and OFTA injection. The effect is mostly transient. While the IVTA injections were more effective for improving CME, ocular hypertension and cataracts developed more often.
authors.affiliation: Department of Ophthalmology, St. Franziskus Hospital, University Duisburg-Essen, DE-48145 Münster, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Roesel
authors.forename: Matthias
authors.initials: M
authors.lastname: Gutfleisch
authors.forename: Carsten
authors.initials: C
authors.lastname: Heinz
authors.forename: Britta
authors.initials: B
authors.lastname: Heimes
authors.forename: Beatrix
authors.initials: B
authors.lastname: Zurek-Imhoff
authors.forename: Arnd
authors.initials: A
authors.lastname: Heiligenhaus
mesh_terms: D002386:Cataract / Q000139:chemically induced; D002908:Chronic Disease; D004333:Drug Administration Routes; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008269:Macular Edema / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009915:Orbit; D012189:Retrospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014605:Uveitis / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide